Prevalence of H. pylori infection and atrophic gastritis in a population-based screening with serum biomarker panel (gastropanel®) in St. Petersburg

Anticancer Research

Volumn 36, Issue 8, 2016, Pages 4129-4138

  Roman, Laslo D ^a   Lukyanchuk, Ruslan ^a   Sablin, Oleg A ^b   Araslanova, Elena I ^b   Eklund, Carita ^c   Hendolin, Panu ^c   Paloheimo, Lea ^c   Syrjänen, Kari ^d,e  

^a Leningrad Regional Oncological Dispensary ^*  (Russian Federation)

^b All Russian Centre of Emergency and Radiation Medicine   (Russian Federation)

^c Departments of Research and Development   (Russian Federation)

^d Biohit Oyj   (Finland)

^e BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

Antrum; Atrophic gastritis; Biomarker; Corpus; Gastric cancer; Gastrin 17; GastroPanel; Helicobacter pylori; Pepsinogens; Population based; Risk factors; Screening; Verification bias

Indexed keywords

BACTERIUM ANTIBODY; GASTRIN 17; IMMUNOGLOBULIN G ANTIBODY; PEPSINOGEN I; PEPSINOGEN II; TUMOR MARKER;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; GASTROPANEL TEST; GASTROSCOPY; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RUSSIAN FEDERATION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STOMACH BIOPSY; STOMACH CANCER; BLOOD; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MASS SCREENING; MICROBIOLOGY; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; RISK FACTORS; ROC CURVE; STOMACH NEOPLASMS;

EID: 84991801137     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C and Rebelo M: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5): E359-386, 2015.
2. Statistics of malignant neoplasms in Russia and countries of CIS in 2007. (Eds) Davydov MI and Aksel EM: Bulletin of Russian Oncological Scientific Center of N. N. Blochin. RAMS 20: (3), 2009.
3. Openko TG, Reshetnikov OV, Kurilovich SA and Simonova GI: Gastric cancer in Novosibirsk at a turn of the millennium (trends of incidence and mortality, possibilities of prevention). Vopr Onkol 59: 708-713, 2013.
4. Kurilovich SA, Belkovets AV, Reshetnikov OV, Openko TG, Malyutina SK, Ragino YI, Scherbakova LV, Leja M, Paloheimo L, Syrjänen K and Voevoda MI: Stomach-specific biomarkers (GastroPanel) can predict the development of gastric cancer in Caucasian population: A longitudinal nested case-control study in Siberia. Anticancer Res 36: 247-254, 2016.
5. Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L and Syrjänen K: Prevalence of H. pylori infection and atrophic gastritis among asymptomatic and dyspeptic adults in Kazakhstan. A Hospital-Based screening with a panel of serum biomarkers. Anticancer Res 33: 4595-4602, 2013.
6. Vohlonen I, Syrjänen K and Karhu J: Serum biomarker-based screening of the risk groups of stomach cancer. Preliminary results of a feasibility study in Finland. Güncel Gastroenteroloji 17: 170-175, 2013.
7. Vohlonen I, Syrjänen K and Karhu J: Serum biomarker-based screening of the risk groups of stomach cancer. Preliminary results of a feasibility study in Finland. Turk J Acad Gastroenterol 12: 47-51, 2013.
8. Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H, Koskenpato J, Sotka M, Turunen M, Sandström R, Ristikankare M, Jussila A and Sipponen P: Nonendoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 15: 885-891, 2003.
9. Miki K: Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels-ABC method. Proc Jpn Acad Ser B Phys Biol Sci 87: 405-414, 2011.
10. Samloff IM, Varis K, Ihamaki T, Siurala M and Rotter JI: Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterol 83: 204-209, 1982.
11. Miki K: Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 9: 245-253, 2006.
12. Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K and Sung J: Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 47: 136-147, 2012.
13. Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol 27: 205-223, 2013.
14. Correa P: Chronic gastritis: a clinico-pathological classification. Am J Gastroenterol 83: 504-509, 1988.
15. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E and Zarama G: Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 50: 4737-4740, 1990.
16. Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V and Jutersek A: Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 57: 324-329, 1994.
17. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M and Nakamura H: Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 109: 138-143, 2004.
18. Correa P: The epidemiology of gastric cancer. World J Surg 15: 228-234, 1991.
19. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52: 6735-6740, 1992.
20. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ and Lomba-Viana H: Serum pepsinogen test for early detection of gastric cancer in a European country. Eur J Gastroenterol Hepatol 24: 37-41, 2012.
21. Germaná B, Di Mario F, Cavallaro LG, Moussa AM, Lecis P, Liatoupolou S, Comparato G, Carloni C, Bertiato G, Battiestel M, Papa N, Aragona G, Cavestro GM, Iori V, Merli R, Bertolini S, Caruana P and Franzé A: Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care. Dig Liver Dis 37: 501-508, 2005.
22. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M and Kurihara M: Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 11: 141-147, 2004.
23. Oksanen A, Sipponen P, Miettinen A, Sarna S and Rautelin H: Evaluation of bood tests to normal gastric mucosa. Scand J Gastroenterol 35: 791-795, 2000.
24. Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, and The Helsinki Gastritis Study Group: Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol 35: 950-956, 2000.
25. Syrjänen KJ, Sipponen P, Härkönen M, Peetsalu A and Korpela S: Accuracy of GastroPanel testing in detection of atrophic gastritis. Eur J Gastroenterol Hepatol 27: 102-104, 2015.
26. Cavallaro LG, Moussa AM, Liatopoulou S, Comparato G, Bertolini S, Merli R, Dal Bo N, Maino M, Bosi S, Cavestro GM, Prati B, Nervi G, Rugge M, Franzé A and DiMario F: Accuracy of serological gastric biopsy in a cohort of dyspeptic patients. 6th European Bridging Meeting in Gastroenterology, Kaunas, Lithuania. A5: p. 32.
27. De Korwin JD, Prucha V, Lozniewski A, Vignaud JM, Conroy MC and Legoedec J: Non-endoscopic diagnosis of atrophic gastritis using the Gastro Panel/GastroSoft. Helicobacter 9: 561-562, 2004.
28. McNicholl AG, Forné M, Barrio J, de la Coba C, González B and Rivera R: Helicobacter pylori Study Group of the Asociación Española de Gastroenterología (AEG). Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur J Gastroenterol Hepatol 26: 941-948, 2014.
29. Iijima K, Abe Y, Kikuchi R, Koike T, Ohara T, Sipponen P and Shimosegawa T: Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol 15: 853-859, 2009.
30. Peitz U, Wex T, Vieth M, Stolte M, Willich S, Labenz J, Jaspersen D, Lind T and Malfertheiner P: Correlation of serum pepsinogens and gastrin-17 with atrophic gastritis in gastroesophageal reflux patients: A matched-pairs study. J Gastroenterol Hepatol 26: 82-89, 2011.
31. Lombardo L, Leto R, Molinaro G, Migliardi M, Ravarino N, Rocca R and Torchio B: Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test. Clin Chem Lab Med 48: 1327-1332, 2010.
32. Nardone G, Rocco A, Staibano S, Mezza E, Autiero G, Compare D, De Rosa G and Budillon G: Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther 22: 1139-1146, 2005.
33. Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H and Talley NJ: Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 43: 1448-1455, 2008.
34. Telaranta-Keerie A, Kara R, Paloheimo L, Härkönen M and Sipponen P: Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4, 256 volunteers without specific complaints. Scand J Gastroenterol 45: 1036-1041, 2010.
35. Zagari RM, Nicolini G, Casanova S, Fiocca R, Pozzato P, Lunedei V, DiMarco M, Luca D, Ricciardiello L, Martuzzi C, Fuccio L, Maltoni S, Grigioni W, Panuccio D and Sipponen P: Diagnosis of atrophic gastritis in the general population based on a combination of three non-invasive tests. Gut 51(suppl 11): A39, 2002.
36. Reichenheim ME and Ponce de Leon A: Estimation of sensitivity and specificity arising from validity studies with incomplete designs. The Stata J 2: 267-279, 2002.
37. Zhou XH and Higgs RE: Assessing the relative accuracies of two screening tests in the presence of verification bias. Stat Med 19: 1697-1705, 2000.
38. Sipponen P, Kekki M, Haapakoski J, Ihamäki T and Siurala M: Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 35: 173-177, 1985.
39. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM and Kuipers EJ: European Helicobacter Study Group. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 61: 646-664, 2012.
40. Israel DA and Peek RM: Review article: pathogenesis of Helicobacter pylori-induced gastric inflammation. Aliment Pharmacol Ther 15: 1271-1290, 2001.
41. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA and Jellum E: Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330: 1267-1271, 1994.
42. Khulusi S, Mendall MA, Patel P, Levy J, Badve S and Northfield TC: Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects. Gut 37: 319-324, 1995.
43. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S and Yamakido M: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 829-832, 2001.
44. Valle J, Kekki M, Sipponen P, Ihamäki T and Siurala M: Longterm course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 31: 546-550, 1996.
45. Kuipers EJ, Uyterlinde AM, Peña AS, Roosendaal R, Pals G and Nelis GF: Long-term sequelae of Helicobacter pylori gastritis. Lancet 345: 1525-1528, 1995.
46. Weck MN, Stegmaier C, Rothenbacher D and Brenner H: Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany. Aliment Pharmacol Ther 26: 879-887, 2007.
47. Pasechnikov V, Chukov S, Fedorov E, Kikuste I and Leja M: Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol 20: 13842-13862, 2014.
48. Sipponen P, Ranta P, Helske T, Kääriäinen I, Mäki T and Linnala A: Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol 37: 785-791, 2002.
49. Sipponen P, Valle J, Varis K, Kekki M, Ihamäki T and Siurala M: Fasting levels of serum gastrin in different functional and morphologic states of the antro-fundal mucosa. An analysis of 860 subjects. Scand J Gastroenterol 25: 513-519, 1990.
50. Leja M, Kupcinskas L, Funka K, Sudraba A, Jonaitis L, and Ivanauskas A: Value of gastrin-17 in detecting antral atrophy. Adv Med Sci 56: 145-150, 2011.
51. Begg CB and Greenes RA: Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 39: 207-215, 1983.
52. Alonzo TA: Verification bias-corrected estimators of the relative true and false positive rates of two binary screening tests. Stat Med 24: 403-417, 2005.